breast cancer

Zev Gartner, PhD, has been named a recipient of the 2013 National Institutes of Health (NIH) Director’s New Innovator Award, which will provide his lab with up to $1.5 million in research funding over the next five years.

It can take just the flick of a genetic switch for breast cells to kick-start the normally well-regulated process of growth seen in puberty, pregnancy, or the menstrual cycle—or the mutation of that switch to initiate the unchecked proliferation of cancer.

Zev Gartner, PhD, a faculty member in the UCSF School of Pharmacy, will lead a US$3.2 million grant to study the interaction of different types of cells in breast cancer at its earliest stages. Research results might ultimately identify new classes of targets for anticancer drugs. The project is...